



# *In silico* antimalarial bioprospecting of neem (*Azadirachta indica*) quinine-derivative alkaloids

Alfin Hidayat<sup>1</sup>, Mamat Sugianto<sup>1</sup>, Ali Budhi Kusuma<sup>1,2</sup>, Lili Suharli<sup>1</sup>, Adhityo Wicaksono<sup>3\*</sup>




**Figure 1.** BioNavi-predicted metabolic pathway of compounds a) A and b) B. Further details on BioNavi results in Supplementary Data.



**Figure 2.** BioNavi-predicted metabolic pathway of compounds c), d), and e). Further details on BioNavi results in Supplementary Data upon request..


**Figure 3.** BioNavi-predicted metabolic pathway of control drug isoxazole pyrimidine (IZP). Further details on BioNavi results in Supplementary Data.



**Figure 4.** BioNavi-predicted metabolic pathway of control quinine. Further details on BioNavi results in Supplementary Data.



**Figure 5.** Swiss Target Prediction pie charts of all five metabolites, on which protein predicted to target the compounds. Pie chart a) to e), respectively referred to Compound A to E (corresponding to Table 1), and ct1) is control drug isoxazole pyrimidine (IZP) and ct2) is control drug quinine.



**Figure 6.** Hydrogen bonds values of the compound-protein pairwise interactions between five tested compounds, two control compounds, and three protein receptors of *Plasmodium falciparum*. Proteins: **a)** PNP, **b)** DHODH, and **c)** EMP1. Ligand-proteins interaction for control compounds: a0) quinine-PNP and b0) isoxazole pyrimidine-DHODH. Tested compound A to E-protein interactions (shown on grid columns 1 to 5, respectively).